Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is headquartered in San Diego, California and currently employs 62 full-time employees. The company went IPO on 2021-03-19. The company is building a pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. Its second product candidate, icanbelimod, is a modulator of S1P1 T cell receptors and is in development for the treatment of ulcerative colitis (UC). Icanbelimod is an orally available, small molecule modulator of S1P1 that is designed to reduce inflammation without killing T cells.
How did CNTB's recent EPS compare to expectations?
The most recent EPS for Connect Biopharma Holdings Ltd is $-2.35, beating expectations of $-1.53.
How did Connect Biopharma Holdings Ltd CNTB's revenue perform in the last quarter?
Connect Biopharma Holdings Ltd revenue for the last quarter is $-2.35
What is the revenue estimate for Connect Biopharma Holdings Ltd?
According to 9 of Wall street analyst, the revenue estimate of Connect Biopharma Holdings Ltd range from $1.42M to $0.0
What's the earning quality score for Connect Biopharma Holdings Ltd?
Connect Biopharma Holdings Ltd has a earning quality score of A-/60.179497. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Connect Biopharma Holdings Ltd report earnings?
Connect Biopharma Holdings Ltd next earnings report is expected in 2026-08-20
What are Connect Biopharma Holdings Ltd's expected earnings?
Connect Biopharma Holdings Ltd expected earnings is $692.92K, according to wall-street analysts.
Did Connect Biopharma Holdings Ltd beat earnings expectations?
Connect Biopharma Holdings Ltd recent earnings of $1.17M does not beat expectations.